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Abstract 
Oral Mucositis is a condition seen in post-treatment mouth cancer patients and is a 
condition of which the pathobiology is not entirely known. It is a condition that shares many 
common pathways with other alimentary tract injuries such as inflammatory bowel disease. 
Mathematical modeling of the system can help to identify gaps in the current knowledge base as 
well as assist in generating  new hypotheses and predicting clinical outcomes of conditions. A 
detailed mathematical model would assist researchers in determining which drug targets are 
worthwhile investigating. Deterministic modeling and Virtual Cell software were used to 
assign rate constants to each pathway and define the model. The model was based on a 
heterogeneous data set of both oral mucositis and inflammatory bowel disease subjects from both 
human and animal models due to the lack of data from a single homogenous cohort. The model 
although not capturing the transient dynamics of the data was able to come to a steady state for 
eight of the nine network components as well as predict the steady state concentration within 
error for six of eight of these components. This model will help to guide further investigation and 
research in this field. It will also help to more fully understand the pathobiology of the condition 
as well as assist in the development of new drugs that can help improve the quality of life 
patients suffering from this very painful condition.   
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Chapter 1: Introduction 
Oral mucositis is a condition that is suffered by nearly all post radiation therapy and 
chemotherapy patients. It is commonly referred to the most significant and debilitating acute 
complication associated with radiation therapy and chemotherapy patients [1]. The condition 
frequently develops seven to fourteen days after treatment is initiated and the outcome is a 
variety of clinical and economic consequences. Oral mucositis can lead to a decrease in a 
patient’s nutrition, daily functioning, and quality of life [2]. It can also lead to interruptions in 
therapy, increased risk in subsequent treatments, and severe pain [1;3]. The disease is 
characterized by ulcerations in the mucosa, giving rise to infection. These infections can have 
possible fatal complications such as bacteremia and sepsis [2].  
Economically, longer hospital stays and additional treatment can be very costly for the 
patient. Patients displaying signs of ulceration on average incur charges of nearly $43,000 higher 
than patients without ulceration [3]. Healing will eventually occur, but there will be residual 
angiogenesis in the tissue and the chemical properties of the tissue that the patient started with 
will not be the same as the properties of the tissue that the patient will end up with. Patients who 
are at high risk for severe oral mucositis are those who have had previous infections, poor oral 
hygiene, or prolonged treatments with steroids or comorbidities [4]. 
Development of a mathematical model describing the condition can have numerous 
benefits. Through the development of the model, one can find gaps in the literature pertaining to 
aspects of the network that are poorly understood. It would be very useful to identify these gaps 
and then focus experimental work in these areas to gain a more complete understanding of how 
network components influence each other. If a mathematical model of differential equations 
describing the changes in protein concentration of network components over time is developed, 
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one could predict what the concentration of a desired species will be at a certain time after 
treatment. One could also model the effect that an experimental drug could potentially have on 
the network and if it is worth taking the time to test the drug in an experimental drug trial. 
 
Chapter 2: Background 
Oral Cavity Mucositis   
Oral cavity mucositis can occur when radiation therapy or chemotherapy is administered. 
Patients receiving aggressive cancer treatment have a 40% chance to develop oral mucositis if 
they are undergoing chemotherapy and have almost a 100% chance to develop oral mucositis if 
they are undergoing radiation therapy, especially in combination with chemotherapy [3]. Due to 
the tissue injury incurred during these treatments, the body’s ability to neutralize the reactive 
oxygen species produced in overwhelmed [3]. The release of reactive oxygen species leads to a 
multitude of tissue damaging events in the epithelium, endothelium, and connective tissues [2]. 
They also cause direct damage in cells, tissues, and blood vessels [1]. The cells of the mucosa are 
especially vulnerable to the cytotoxic effects both radiation therapy and chemotherapy because 
of the high turnover rates of the cells in the tissue [1]. Each cell will be replaced in 3 to 5 days 
and the tissue as a whole will be replaced every 7 to 14 days [1]. 
 Early research suggested that oral mucositis occurred only due to DNA injury in the 
epithelium [1]. DNA injury in the epithelium leads to cell death and the thinning of the mucosal 
epithelium. It was thought that this thinning of the epithelium was exclusively what leads to 
ulceration in the mucosa [1]. It was later found that radiation therapy and chemotherapy induced 
oral mucositis was not only due to injury in the epithelium but also due to events occurring in the 
lower layers of tissue [3]. 
 6 
In one such event, the transcription factor NF-κB is up-regulated leading to the 
production of the pro-inflammatory cytokines IL-6, IL-1β, and TNF-α as well the production of 
COX-2 from arachidonic acid [2;5]. In its inactive form, NF-κB is located in the cytoplasm 
bound to unphosphorylated IκBα [6]. NF-κB is activated when reactive oxygen species, TNF-α, 
or any other cellular signal leads to the activation of IκB kinase or IKK [6]. IKK will 
phosphorylate IκBα leading to its degradation [6]. The degradation of IκBα activates NF-κB. 
Activated NF-κB will enter the nucleus and trigger the transcription of many genes, including 
the genes for IκBα and A20. IκBα will bind to NF-κB deactivating it and returning it to the 
nucleus. A20 is responsible for inhibiting IKK [6]. Therefore, after an initial spike of activated 
NF-κB, the up-regulation of inhibitory genes will lead to a decrease in the concentration of 
activated NF-κB to a new steady state dependant on the presence of IKK producing signals.    
COX-2 is an enzyme that leads to the production of prostaglandins such as PGE2, PGI2, 
and TXA2 by catalyzing the synthesis of prostaglandins PGH2 and PGD2 from arachidinic acid 
[5] [7]. PGH2 and PGD2 are quickly converted to PGE2, PGI2, and TXA2 by PGE synthase, 
prostacyclin synthase, and thromboxane synthase respectively [8]. The production of these 
prostaglandins are believed to cause inflammation, angiogenesis by activating vascular 
endothelial growth factor, and even possibly feedback to produce more of the COX-2 enzyme 
[5]. Prostaglandins also help protect the mucosa by inhibiting macrophages and T-cell responses 
[7]. The pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 are believed to cause tissue injury 
through the production of matrix metalloproteinases as well as assist in the further up-regulation 
of the NF-κB transcription factor [1;2;9].  
 Tissue damage in the mucosa due to radiation therapy and chemotherapy can also be 
caused through the ceramide pathway. Both radiation therapy and chemotherapy lead to the 
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hydrolization of the cell-membrane lipid sphingomyelin through the activation of 
sphingomyelinase and ceramide synthase [1]. Ceramide synthase or sphingomyelinase can 
initiate the ceramide pathway, which leads to apoptosis [1;3]. It is probable that TNF-α 
contributes to the upregulation of sphingomyelinase and helps promote apoptosis through the 
ceramide pathway [10]. 
 Finally, radiation therapy and chemotherapy causes the breakup of fibronectin in the 
connective tissue [1]. The breakup of fibronectin stimulates macrophages, which in turn 
stimulate matrix metalloproteinases (MMP’s) [1]. MMP’s cause direct tissue injury and also lead 
to increased levels of TNF-α [1]. TNF-α and IL-1β in turn feedback and stimulate the 
production of more MMP’s and therefore greater tissue injury [1]. 
 The ulceration phase of oral mucositis begins when the tissue becomes sufficiently 
damaged and gaps form in the tissue layers. Colonizing microorganisms then invade the tissue 
and can cause life-threatening sepsis [1]. The products released by the microorganisms will lead 
to the activation of macrophages, which in turn result in increasing levels of cytokines in the 
tissue [1]. This is the most painful phase of the condition [1]. 
 Tissue healing will naturally occur 3-6 weeks after the discontinuation of cancer 
treatment [1]. Even though the tissue will heal and look normal, in fact many changes still are 
present. There is residual change in the molecular and cellular environment as well as residual 
angiogenesis [1;3]. Patients who have developed oral mucositis in the past will have increased 
risk of developing oral mucositis again if radiation treatment or chemotherapy is needed again in 
the future [1]. The pathology of the disease is summarized in Figure 1. 
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Figure 1: Pathology of Oral Mucositis - The key species and interactions of oral mucositis are identified in this 
network diagram. Radiation therapy (RT) and chemotherapy (CT) cause the up-regulation of reactive oxygen 
species (ROS) which in turn leads to a cascade of events resulting in clonologic cell death, angiogenesis, apoptosis, 
and tissue injury. 
 
 Oral mucositis will begin to manifest itself in radiation therapy patients when doses 
approach 1000 to 2000 cGy [1]. It most commonly is manifested when doses exceed 3000 cGy, 
and is almost certain to be manifested in patients receiving doses greater than 5000 cGy [1]. 
Symptoms develop within 7 to 14 days after the start of treatment and ulceration symptoms peak 
5 to 6 weeks after the start of treatment [1;3]. 
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Inflammatory Bowel Disease  
Inflammatory bowel disease is a condition that encompasses two different types of 
chronic intestinal inflammation [11]. These two conditions are Crohn’s disease, which is 
characterized by Th1 cytokines, and ulcerative colitis, which is characterized by Th2 cytokines 
[12]. The pathology of inflammatory bowel disease and more specifically that of Crohn’s disease 
share many common molecular pathways with the pathology of oral mucositis. A summary of 
the pathology of Crohn’s disease can be seen in Figure 2. 
 
Figure 2: Pathology of Inflammatory Bowel Disease (Crohn’s Disease) - The major species and interactions in 
Crohn's disease are outlined in this network diagram. The activation and up-regulation of NF-κB by reactive oxygen 
species and inflammatory cytokines leads to the production of more cytokines as well as the up-regulation of the 
COX-2 pathway. 
 
 As in oral mucositis, the up-regulation of pro-inflammatory cytokines in inflammatory 
bowel disease leads to tissue inflammation and damage [13;14;15]. Prominent cytokines up-
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regulated in Crohn’s disease include IL-12, IL-18, IL-23, IFN-γ, as well as TNF-α, IL-1β, and 
IL-6 [15;16;17]. Reactive oxygen species also contribute to the pathogenesis of inflammatory 
bowel disease and in of themselves cause much tissue damage [18]. Reactive oxygen species 
lead to the up-regulation of NF-κB in the gut, which in turn leads to the up-regulation of many 
pro-inflammatory cytokines including the ones aforementioned [18;19]. Pro-inflammatory 
cytokines, such as TNF-α, IL-1β, and IL-18, also lead to the up-regulation of more of the NF-κB 
transcription factor, creating a positive feedback mechanism allowing for the perpetuation of 
inflammation in the gut [15]. The tissue damaging effects of the pro-inflammatory cytokines 
include the stimulation of myofibroblasts to synthesize increased amount of matrix 
metalloproteinases, which causes mucosal degradation as they also do in observed mucositis in 
the oral cavity [17]. Keratinocyte growth factor is also induced by cytokines, but primarily by 
TNF-α, and it also produces changes in the gut [15]. One of these changes is the hyperplasia 
observed in crypt cells in this condition [15]. 
 The COX-2 enzyme has also been observed to be up-regulated by NF-κB in the mucosa 
of inflammatory bowel disease patients as it has been observed in the mucosa of patients 
suffering from oral mucositis [19]. Whereas COX-1 expression in inflammatory bowel disease 
patients has been observed to be similar to that of patients without inflammatory bowel disease, 
COX-2 expression increases from almost undetectable levels in normal mucosa to high levels 
during the manifestation of inflammatory bowel disease [19]. With the up-regulation of COX-2 
follows the up-regulation of prostaglandins such as PGE2, PGI2, and TXA2 [20]. The 
prostaglandins participate in the regulation of cytokine production in mononuclear cells and 
possible in lymphocytes and macrophages also [20]. It is also possible that the diarrhea caused 
by inflammatory bowel disease may be in part due to increased prostaglandin production [20].  
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 Angiogenesis, or the production of new blood vessels, is also a symptom of inflammatory 
bowel disease as it is in oral mucositis [14]. Angiogenesis is promoted through the production of 
vascular endothelial growth factor (VEGF), which is up regulated by PGE2 [21;22]. 
Angiogenesis, while characteristic of inflammation, is required for the development and repair of 
all tissues [21]. Without the induction of angiogenesis the spontaneous healing seen in oral 
mucositis and in inflammatory bowel disease would not occur.     
Deterministic Modeling  
The common network can be modeled using deterministic modeling which will allow one 
to observe the changes in concentration of the proteins involved in the network [23]. A system of 
ordinary differential equations can be set up to model the change in protein concentration of a 
network component per unit time as a function of components producing the protein and 
components using up the protein. To specify the model rate constants are assigned to each 
reaction pathway. In order to calculate the rate constants for all of the reactions, there must be 
data available describing the dynamic behavior of the concentration of each protein in the 
network over a period of time. Once the data is obtained, the program Virtual Cell can be used 
to obtain estimates for each rate constant. 
The Virtual Cell Software Package 
 The program Virtual Cell was instrumental in this research to estimate the rate 
constants for a given data set. Virtual Cell is a computational environment which is designed 
for cell biologists as well as for mathematical biologists and bioengineers to aid in the 
construction of cell biological models and in the generation of simulations from them [24;25]. 
The program contains a biology-oriented graphical user interface, which allows one to assemble 
a model by specifying the molecules, reactions, and structures involved [24]. It provides a 
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framework for modeling biochemical, electrophysiological, and transport phenomena while still 
taking into account the sub cellular localization of the molecules that take part in them [24]. 
 The program allows the user to define both spatial and non-spatial models [24;25]. Using 
spatial models, one can specify compartments and geometry, whereas using non-spatial models 
one can create models assuming well-mixed compartments [24;25]. Once simulations are 
produced, they can be compared to the experimental data. If the simulation matches the data, 
new simulations can be run under different conditions to predict results [24]. Virtual Cell can 
also be used to perform parameter estimation analyses after specification of a data set and a 
model [25].       
 
Chapter 3: Results  
Model Development  
Nine key components were identified in the COX-2 mediated oral mucositis network. 
These components were NF-κB, COX-1, COX-2, TNF-α, IL-1β, IL-6, PGE2, PGI2, and TXA2. 
The network showing the reactions and feedback loops interconnecting these nine components is 
shown in Figure 3.  
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Figure 3: Core Mucositis Network - The key species and interactions common to both the oral mucositis and 
inflammatory bowel disease networks are captured in this diagram. The up-regulation of NF-κB by reactive oxygen 
species and inflammatory cytokines leads to the production of more inflammatory cytokines as well as to the 
production of prostaglandins by the COX-2 pathway. 
 
The three feedback loops taken into account in the core network was the feedback of 
TNF- α, IL-1β, and PGE2 to up-regulate more of the NF-κB transcription factor. 
The Bio-model tool in Virtual Cell was used to input each species into a single 
compartment entitled “Mucosa”. Reaction pathways were then mapped according to the network 
previously discussed. Virtual Cell allows the user to specify the kinetics for each reaction 
pathway connecting two components. For each reaction, mass-action kinetics was selected and a 
rate constant was specified. A total of 27 unknown rate constants were assigned to the 27 
reaction pathways in this network.  
Each component in the oral mucositis network was modeled using an ordinary 
differential equation describing the dynamic behavior of the species concentration over time. 
Each differential equation was created by subtracting all of the terms that lead to the usage of the 
species from all of the terms that lead to the production of the species. All species except for 
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COX-1 are dependant on the concentration of another species in the network. The differential 
equations describing the nine components in the network are as follows, 
d[NF −κB]
dt
= k1 + k2 *[TNF −α]+ k3 *[IL −1β]+ k4 *[PGE − 2]− k5 *[NF −κB]
d[TNF −α]
dt
= k6 + k7 *[NF −κB]− k8 *[TNF −α]
d[IL −1β]
dt
= k9 + k10 *[NF −κB]− k11 *[IL −1β]
d[COX − 2]
dt
= k12 − k13 *[COX − 2]
d[COX −1]
dt
= k14 − k15 *[COX −1]
d[PGE − 2]
dt
= k16 *[COX − 2]+ k17 *[COX −1]− k18 *[PGE − 2]
d[PGI − 2]
dt
= k19 *[COX − 2]+ k20 *[COX −1]− k21 *[PGI − 2]
d[TXA − 2]
dt
= k22 *[COX − 2]+ k23 *[COX −1]− k24 *[TXA − 2]
d[IL − 6]
dt
= k25 + k26 *[NF −κB]− k27 *[IL − 6]
 
Figure 4: Differential Equations Describing the Oral Mucositis Model - The nine key species of the mucositis are 
modelled by the use of ordinary differential equations. 
 
where the concentration of each of the nine species is modeled as a function of time. The units of 
the concentrations of each species described by the differential equations are shown in Table1. 
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Table 1: Concentration Units of Species in Model ODE’s 
Species Units 
NF-κB uM
day
  
TNF-α mRNA _ norm _ to_GAPDH
day
 
IL-1β mRNA _ norm _ to_GAPDH
day
 
COX-2 ng_ mRNA
day
 
COX-1 ng_ mRNA
day
 
PGE-2 pg /100mg_ tissue
day
 
PGI-2 pg /ml
day
 
TXA-2 pg /ml
day
 
IL-6 mRNA _ norm _ to_GAPDH
day
 
   
 The Bio-model in Virtual Cell was then used to generate a Math-model in the same 
application. The Math-model in Virtual Cell generated a set of differential equations identical 
to the set described in Figure 4 confirming their validity. In order to run a simulation in Virtual 
Cell the rate constants needed to be specified. Since there were no literature values reported for 
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any of the rate constants they had to be derived from the data collected from the literature using 
the regression analysis tool in Virtual Cell.  
Data Collection 
 In the literature survey it was found that there is very little published data concerning the 
dynamics of any of the oral mucositis pathway components. Although it is preferable to use a 
single homogenous cohort when developing a model such as this, the lack of necessary published 
data made it necessary to collect a heterogeneous set of data. Using a systems biology approach, 
one can collect data from a variety of similar conditions sharing the same pathway and integrate 
the data to form a uniform computational model. Since inflammatory bowel disease and more 
specifically Crohn’s disease shares the same pathway as oral mucositis, data was taken from 
Crohn’s disease patients and animal models to help populate the model.  
 Gaps in the literature were also identified in the survey of inflammatory bowel disease. 
After combination of oral mucositis data with inflammatory bowel disease data from both human 
and animal models, it was found that there is still a lack of data describing the dynamics of PGI2 
and TXA2. There is also very little data describing the dynamics of any of the network 
components in oral mucositis alone.      
It is difficult to measure the concentration of the NF-κB transcription factor in the cell 
over time as once it is activated it is used up very quickly [6]. Data describing the dynamic 
behavior of NF-κB was taken from a mathematical model created by Lipniacki et al to model 
activate and inactive NF-κB in the cell after signaling from extracellular signals such as TNF-α 
[6]. The model was based on a two-compartment system, the cytoplasm and the nucleus [6]. 
Since it is the free, activated NF-κB in the nucleus that leads to the up-regulation of the 
inflammatory cytokines and COX-2, it was the free, active NF-κB data generated in the model 
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that was used for the oral mucositis model. The model is based on the assumptions that hundreds 
of mRNA transcripts can be translated per seconds and that the A20 inhibitor of IKK acts at the 
level of IKK and not somewhere upstream of IKK [6].    
 Data describing the dynamic behavior of the TNF-α, IL-1β, and IL-6 cytokines was taken 
from models of rat colitis induced by TNBS in 50% ethanol. 1.2 mL of the TNBS solution was 
injected into the distal colon of the rats [26]. The data was gathered using a semi-quantitative 
RT-PCR assay and the data was measured in the amount of cytokine mRNA relative to the 
amount of GAPDH mRNA in the sample [26]. The section of the colon observed was the section 
from the cecum to the anus [26]. Each experimental group anesthetized at each time point was 
made up of a maximum of five animals [26]. The literature study utilized took data at the 0, 1, 7, 
14, 28, and 45-day time points [26].  
 COX-1 and COX-2 data was taken from obtained clinical trial data [8]. In the trial there 
were three patients. Samples were taken 10 days pre-radiation treatment, as well as 10, 28, and 
100 days after the administration of the first dose of radiation therapy. Samples that were taken 
were biopsy and blood samples from the bucal layer of the oral mucosa. The COX-1 and COX-2 
data taken were measured in ng of mRNA. 
 Data regarding the dynamic behavior of prostaglandin E2 was found in the literature 
where C57BL/6 mice were exposed to 3% (w/v) dextran sulfate sodium (DSS) to induce chronic 
colitis [7]. The mice used in the study were 7-12 weeks old and weighed 18-22 g [7]. Data was 
taken at times of 0, 1, 3, 5, 12, 19, 26, and 34 days. Samples were analyzed by ELISA and 
protein values were measured in pg/100 mg of colonic tissue biopsied [7]. 
 PGI2 and TXA2 data was found in the literature where epithelial and mononuclear cells 
cells were isolated from intestinal mucosa in healthy and inflammatory bowel disease patients 
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[27]. The study consisted of four Chron’s Disease patients who had not taken any steroids up to 
one month prior to the operation [27]. Steroids may inhibit both of these prostaglandins [27]. 
Samples were determined using a radioimmunoassay and were measured in pg/ml [27]. Samples 
were taken at assumed steady state levels. There was no data describing the dynamic data of 
either PGI2 or TXA2. The data from this study suggested that enhanced synthesis of both PGI2 
and TXA2 in inflammatory bowel disease is mainly due to increased synthesis of both PGI2 and 
TXA2 in mononuclear cells [27]. There was a four-fold increase in the change in secretion of 
PGI2 and TXA2 in mononuclear cells as compared to the change in epithelial cells [27].            
Parameter Estimation  
The parameter estimation tool in Virtual Cell was then used to analyze a data set and 
predict values for all 27 rate constants. Initial guesses were taken from previously run regression 
tests. Once the regression analysis tool had predicted a set of rate constants, a simulation was run 
and the model was compared to the experimental data. The rate constants were then re-analyzed 
using new initial guesses as well as any new data that became available. The most accurate set of 
rate constants predicted by Virtual Cell, which were used in the simulation to generate the 
model can be found in Table 2. 
Table 2: Rate Constant Estimations for Model ODE’s 
Rate Constant Value Units Reference 
k1 12.49 uM _ NF −κB
day
 
[6] 
k2 10.10 uM _ NF −κB
day * mRNA
 
[6;26] 
k3 12.21 uM _ NF −κB
day * mRNA
 
[6;26] 
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k4 2.71*10-6 uM _ NF −κB
day * pg /100mg_ tisue
 
[6;7] 
k5 53.17 1
day
 
[6] 
k6 463.67 mRNA _ norm _GAPDH
day
 
[26] 
k7 5.28*10-19 mRNA _ norm _GAPDH
day * uM _ NF −κB
 
[6;26] 
k8 1,269.85 1
day
 
[26] 
k9 105.16 mRNA _ norm _GAPDH
day
 
[26] 
k10 100.97 mRNA _ norm _GAPDH
day * uM _ NF −κB
 
[6;26] 
k11 90.67 1
day
 
[26] 
k12 119.97 ng_ mRNA
day * um _ NF −κB
 
[8] 
k13 2.71 1
day
 
[8] 
k14 1,738.18 ng_ mRNA
day
 
[8] 
k15 6.12*10-18 1
day
 
[8] 
k16 8.88*10-19 pg /100mg_ tissue
day * ng _ mRNA
 
[7;8] 
k17 40.54 pg /100mg_ tissue
day * ng _ mRNA
 
[7;8] 
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k18 0.04 1
day
 
[7] 
k19 51.63 pg /ml
day * ng _ mRNA
 
[8;27] 
k20 448.04 pg /ml
day * ng _ mRNA
 
[8;27] 
k21 0.02 1
day
 
[27] 
k22 55.59 pg /ml
day * ng _ mRNA
 
[8;27] 
k23 3,675.93 pg /ml
day * ng _ mRNA
 
[8;27] 
k24 0.03 1
day
 
[27] 
k25 36.36 mRNA _ norm _GAPDH
day
 
[26] 
k26 56.80 mRNA _ norm _GAPDH
day * uM _ NF −κB
 
[8;26] 
k27 351.37 1
day
 
[26] 
  
Literature Data vs. Model Predictions  
 Simulations in Virtual Cell were run using the Runge-Kutta-Fehlberg (Fifth Order, 
Variable Time Step) solver. Each simulation was run from time t = 0 days to time t = 50 days. 
The time interval was chosen to match the time interval over which the majority of the 
experimental component data was specified. The simulation data generated from the model was 
plotted and compared to the experimental and literature data collected.  
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Figure 5: Dynamic Behavior of NF-κB - The NF-κB data is compared against the Virtual Cell™ model simulation 
where the blue markers represent the data and the green line represents the model simulation [6]. 
  
 Figure 5 shows the comparison of the NF-κB model to the simulation data collected from 
the literature. The NF-κB transcription factor was found in the literature to be up regulated to a 
maximal concentration of approximately 0.28 uM in 1.25 hours [6]. It then falls to a steady state 
concentration of 0.08 uM approximately 6 hours after initial activation [6]. The model was able 
to closely approximate this behavior as the NF-κB reaches a plateau concentration at 
approximately the same time and at a concentration of 0.083 uM.  
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Figure 6: Dynamic Behavior of TNF-α - The TNF-α  data is compared against the Virtual Cell™ model simulation 
where the blue markers represent the data and the green line represents the model simulation [26]. 
  
 Figure 6 shows the comparison of the TNF-α model compared to the data found in the 
literature. TNF-α was found in the literature to reach a peak concentration of 0.78 ± 0.2 units 
mRNA norm to GAPDH in 1 day and then move to a steady state concentration of 0.35 ± 0.13 
units mRNA norm to GAPDH in approximately 45 days [26]. The TNF-α model was very 
inaccurate in describing the dynamic nature of the TNF-α literature data. The model predicts a 
very fall rise to a plateau concentration of 0.362 units mRNA norm to GAPDH. The plateau 
concentration of the model was very close to the steady state concentration of the data and was 
able to predict it within error.    
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Figure 7: Dynamic Behavior of IL-1β - The IL-1β  data is compared against the Virtual Cell™ model simulation 
where the blue markers represent the data and the green line represents the model simulation [26]. 
  
 Figure 7 displays the comparison of the literature data found for IL-1β to the model 
generated to describe the species. The literature data collected for IL-1β shows that IL-1β is up 
regulated very quickly. It plateaus and reaches a peak concentration of 1.3 ± 0.1 units mRNA 
norm to GAPDH in 14 days [26]. It then falls and reaches a new steady state concentration of 
0.95 ± 0.1 units mRNA norm to GAPDH at the 45 day mark. The IL-1β model while fails to 
capture the dynamics of the data and it predicts a very quick rise to a plateau concentration. The 
model reaches a plateau concentration of 1.103 units mRNA norm to GAPDH at the 0.1 day 
mark which is much earlier than the data reaches the new steady state. In reaching this new 
steady state at an earlier time point it also does not recognize any peak in IL-1β concentration 
before it falls to the new steady state concentration. The plateau concentration of the model does 
not accurately predict the steady state concentration of the data within error, but it falls just 
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slightly above the upper range of acceptable error.   
Figure 8: Dynamic Nature of COX-2 - The COX-2  data is compared against the Virtual Cell™ model simulation 
where the blue markers represent the data and the green line represents the model simulation [8]. 
  
 Figure 8 shows the comparison between the literature data describing the dynamics of 
COX-2 and the model generated to describe the behavior of COX-2. The COX-2 data gathered in 
the clinical trial study was found to oscillate to a peak of 0.0677 ± 0.067 ng mRNA at t = 10 days 
and then fall to 0.019 ± 0.0156 ng mRNA at t = 28 days. It then proceeds to rise again to 0.096 ± 
0.102 ng mRNA at t = 100 days [8]. Steady state was assumed to have been reached after 100 
days. The COX-2 model predicts a stable amount of COX-2 present in the mucosa over the 
entire time range. No fluctuations or dynamic behavior of any kind is seen in the model. The 
model reaches a plateau concentration of 0.09 ng mRNA which is slightly less than the steady 
state concentration of COX-2 in the data set, but the prediction of the data by the model falls 
within the acceptable error range.    
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Figure 9: Dynamic Behavior of COX-1 - The COX-1  data is compared against the Virtual Cell™ model simulation 
where the blue markers represent the data and the green line represents the model simulation [8]. 
  
 Figure 9 shows the comparison between the COX-1 model and the data gathered 
describing the dynamics of COX-1 in the literature. The COX-1 data collected in the clinical trial 
study was also found to oscillate much like the COX-2 data. The amount of COX-1 in the 
mucosa increased to 0.853 ± 0.51 ng mRNA at t = 10 days. It then fell to 0.270 ± 0.042 ng 
mRNA at t = 28 days before rising again to 0.443 ± 0.212 ng mRNA at t = 100 days [8]. Steady 
state was again assumed to be reached by the 100-day mark. The COX-1 model does not capture 
the dynamic nature of the experimental data, but it does reasonable predict the COX-1 steady 
state concentration. The model predicts that the amount of COX-1 in the mucosa at steady state 
will be 0.417 ng mRNA. The model also falls within the error bars for each experimental data 
point except for the point at t = 28 days where the model falls just outside of the error bars.  
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Figure 10: Dynamic Behavior of PGE2 - The PGE2  data is compared against the Virtual Cell™ model simulation 
where the blue markers represent the data and the green line represents the model simulation [7]. 
 
 Figure 10 displays the literature data collected for PGE2 in comparison to the model 
generated to describe the dynamics of PGE2. The PGE2 data found in the literature was highly 
variable. The concentration of PGE2 initially decreases, but then rebounds to a peak 
concentration of 3,800 ± 800 pg/100 mg colonic tissue at t = 19 days and then falls back to a new 
steady state concentration of 2400 pg/100 mg colonic tissue [7]. The PGE2 model predicts a 
steady decline of the species to a plateau concentration of 792.6 pg/100 mg colonic tissue. The 
model fails to capture the dynamics of the literature data and it is not able to predict the final 
steady state of the data within error. 
 27 
Figure 11: Dynamic Behavior of IL-6 - The IL-6  data is compared against the Virtual Cell™ model simulation 
where the blue markers represent the data and the green line represents the model simulation [26]. 
  
 Figure 11 shows the IL-6 model generated in comparison to the literature data collected. 
The literature data collected for IL-6 showed an initial spike from a very low initial 
concentration of IL-6 to a concentration of 1.25 ± 0.1 units mRNA norm to GAPDH in 1 day 
[26]. The concentration of IL-6 then fell and reached a new steady state at a concentration of 0.3 
± 0.05 units mRNA norm to GAPDH [26]. The IL-6 model was not able to capture the dynamics 
of the system or predict the steady state concentration of the species within error. The steady 
state predicted by the model was 0.123 units mRNA norm to GAPDH, which was well just 
below the uncertainty range of the literature value. The model was also not able to capture the 
initial spike of IL-6 in the first few days after treatment. 
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Figure 12: Dynamic Behavior of PGI2 - The PGI2 data is compared against the Virtual Cell™ model simulation 
where the blue markers represent the data and the green line represents the model simulation [27]. 
 
 Figure 12 shows the PGI2 model in relation to the literature data accumulated for the 
species. The only literature data gathered for PGI2 specified a normal concentration of PGI2 in 
the mucosa, which is 6,926.4 ± 3,463.2 pg/ml, and a new steady state concentration of PGI2 in 
the mucosa after the activation of the COX-2 pathway in inflammatory bowel disease [27]. As 
occurs in the rest of the network, the new steady state was assumed to have been met by the 45-
day mark. The new steady state concentration of PGI2 is 10,389.6 ± 3,078.4 pg/ml [27]. The 
PGI2 model predicts a rise to the new steady state concentration in about 33 days. It also predicts 
the new steady state value of PGI2 as 8,548.39 pg/ml, which falls between the regions of 
uncertainty in the literature data.    
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Figure 13: Dynamic Behavior of TXA2 - The TXA2 data is compared against the Virtual Cell™ model simulation 
where the blue markers represent the data and the green line represents the model simulation [27]. 
  
 Figure 13 shows the model generated for TXA2 in relation to the literature data located 
pertaining to TXA2. As with the PGI2 literature data, the data found in the literature describing 
the behavior of TXA2 only specified a healthy concentration of TXA2 in the mucosa as well as a 
new steady state concentration of TXA2 in the mucosa after the activation of the COX-2 pathway 
in inflammatory bowel disease [27]. The healthy concentration of TXA2 in the mucosa is 7,696 ± 
1,539.2 pg/ml and the new steady state after the activation of inflammatory bowel disease is 
31,553.6 ± 11,544 pg/ml [27]. The TXA2 model predicts the concentration of TXA2 will increase 
at a slower rate as time increases. Although the model reasonably predicts the new steady state to 
be 37,704.64 pg/ml, which is within the range of uncertainty of the literature steady state value, 
the dynamics that the model predicts are very unlikely. If the model were to continue to be valid 
for later time points, the concentration of TXA2 would continue to increase to a plateau 
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concentration, which will possibly be greater than the steady state of TXA2 within error.  
 In summary, seven of the nine major network components modeled reached a plateau 
concentration. The only components not to reach a plateau concentration were PGE2 and TXA2. 
Of the seven network components reaching steady state, the model was able to predict the steady 
state of the species to within error in five cases.   
 
Chapter 4: Discussion 
 The largest contributor to the model failing to capture the dynamics of the system is the 
many gaps of knowledge in the literature. The lack of kinetic data in the literature is one of main 
sources of error. When very little in the way of kinetics is specified, Virtual Cell™ cannot be 
expected to capture them. Also, since the pathways of the network are still under investigation 
and all feedback loops in the system have not yet been determined the specification of the 
network to Virtual Cell™ may also be inaccurate. In fact, one the most important outcomes of 
this investigation and development of this preliminary model is the identification of gaps in the 
knowledge and prediction of feedback loops or pathways that seems to exist that have not been 
previously identified.  
 As mentioned, no data was found describing the dynamics of PGI2 and TXA2 in 
inflammatory bowel disease, and no data at all was found describing the dynamics of any of the 
species in oral mucositis alone. Also, the data found in the literature describing the dynamics of 
the species in inflammatory bowel disease was very few. Therefore, the need for new studies and 
new data describing all of the species in the network are desperately needed. Central of the 
network is the up-regulation of NF-κB and COX-2. No experimental data was found for the NF-
κB transcription factor. It is critical that further investigation is done into the dynamics of this 
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component. The up-regulation of COX-2 follows the up-regulation of NF-κB. Accurately 
understanding the nature of COX-2 protein concentrations throughout the tissue injury and tissue 
healing process is critical as the COX-2 in the mucosa leads to the up-regulation of 
prostaglandins and cytokines, which cause tissue damage and angiogenesis. Currently, the study 
of COX-2 included in the model contains only three patients [8]. Data accumulated from three 
patients is not enough to observe a trend in the data or understand the true dynamics of the 
species. More data will need to be accumulated from more patients before the model will be able 
to be made more accurate.  
 Finally, one additional element to be considered in future models is the effectiveness of a 
COX-2 inhibitor in reducing the symptoms of oral mucositis. COX-2 inhibitors have been 
proven in rat colitis models to reduce diarrhea and weight loss as well as cause a significant 
reduction in colonic injury and PGE2 levels [28;29]. A full study into the molecular events 
occurring in both oral mucositis and in inflammatory bowel disease could lead to a better 
understanding of the effects of COX-2 on the mucositis network and could provide a comparison 
to model predictions. Other therapeutic interventions studied for the treatment of oral mucositis 
have been cryotherapy, growth factor treatment, anti-inflammatory agent treatment, antioxidant 
treatment, antimicrobial agent treatment, and laser therapy [30]. As the model is developed, 
predictions can be postulated as to the outcomes of these treatments and their relative 
effectiveness, and data collected from these cases would go a long way in improving the current 
knowledge of oral mucositis.    
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Chapter 5: Conclusions 
 In conclusion, the preliminary mathematical model developed to describe the oral 
mucositis network based on a heterogeneous set of data collected from literature studies of oral 
mucositis as well as literature studies of inflammatory bowel disease in both human and animal 
models was able to predict in five of nine cases the steady state concentration of the network 
component. Although the model failed to capture the dynamics of the data collected, the 
collection of more data as well as more investigation into the pathogenesis of both oral mucositis 
and inflammatory bowel disease will likely yield more accurate results in the future.  
 
Chapter 6: Future Recommendations 
 The current model can be improved in many ways, one of which is the accumulation of 
data from a single cohort of test subjects. A more mature model based on a single homogenous 
cohort will yield many benefits. Future laboratory work and clinical investigations will be greatly 
accelerated, as the model will provide preliminary predictions of outcomes. Development of a 
mature model will also shed light on the mechanisms by which oral mucositis is specific to 
certain areas of the mucosa and why other non-oral mucosa are more resistant and rarely affected 
by high-dose cancer radiation therapy and chemotherapy. A sensitivity analysis will be 
conducted to analyze the accuracy of the model parameters. Other future work on the model 
includes a stability analysis, which will test how stable the model is in response to perturbation.  
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